Ikena Oncology Inc. (NASDAQ: IKNA) Stock Information | RedChip

Ikena Oncology Inc. (NASDAQ: IKNA) Listen to this Section


$1.71
+0.0250 ( +1.49% ) 99.6K

Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.

Market Data


Open


$1.71

Previous close


$1.68

Volume


99.6K

Market cap


$82.52M

Day range


$1.68 - $1.73

52 week range


$1.02 - $5.21

Insider Ownership Transactions

Total Amount Purchased: -982,740.00 | $ -1,675,571.70

Date Type Amount Purchased Purchaser
2024-06-10 Sale -17520.00 Dukes Iain D.
2024-06-10 Sale -17520.00 Stampacchia Otello
2024-06-10 Sale -17520.00 FORMELA JEAN FRANCOIS
2024-06-10 Sale -17520.00 Bonita David P
2024-06-10 Sale -17520.00 Hughes Owen
2024-06-10 Sale -17520.00 Koehler Maria
2024-06-10 Sale -17520.00 Wooster Richard
2024-03-05 Sale -579100.00 Germa Caroline
2024-02-02 Sale -100000.00 Ecsedy Jeffrey
2024-02-02 Sale -181000.00 Marango Jotin

SEC Fillings


Form Type Description Pages Date
10-q Quarterly Reports 58 Aug 08, 2024
8-k 8K-related 13 Jul 12, 2024
8-k 8K-related 13 Jun 10, 2024
4 Insider transactions 1 Jun 10, 2024
4 Insider transactions 1 Jun 10, 2024
4 Insider transactions 1 Jun 10, 2024
4 Insider transactions 1 Jun 10, 2024
4 Insider transactions 1 Jun 10, 2024
4 Insider transactions 1 Jun 10, 2024
4 Insider transactions 1 Jun 10, 2024

Latest News


Terms and Agreement

Please agree to the terms to continue using the chat feature.